NCT04207320

Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Severe Sickle Cell Disease

Hematopoietic Stem Cell Transplantation for Patients With Severe Sickle Cell Disease Using Myeloablative Conditioning and αβ+ T-cell Depleted Hematopoietic Stem Cells From Partially Matched Familial Donors

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 2 Years – 25 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to develop a safe and curative stem cell transplant approach to treating sickle cell disease by assessing the safety of haploidentical hematopoietic stem cell transplantation using αβ+ T-cell depletion for children and adolescents with severe sickle cell disease (SCD).

Conditions

• Sickle Cell Disease

Interventions

Type	Name	Description
DEVICE	αβ+ T-cell depletion with Miltenyi CliniMACS system	Haploidentical CD34+ megadose hematopoietic stem cell transplant in which cells are purified using the Miltenyi CliniMACS system designed for αβ+ T-cell receptor selection using immunomagnetic beads.

Timeline

• Start date: 2020-04-07
• Primary completion: 2023-05-22
• Completion: 2023-05-22
• First posted: 2019-12-20
• Last updated: 2024-12-04
• Results posted: 2024-12-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study